Do differences in cell lines and methods used for calculation of IC₅₀ values influence categorisation of drugs as P-glycoprotein substrates and inhibitors?

References

• Agarwal S, Arya V, Zhang L. 2013. Review of P-gp inhibition data in recently approved new drug applications: utility of the proposed [I1]/IC50 and [I2]/IC50 criteria in the P-gp decision tree. J Clin Pharmacol. 53(2):228–233.
   PubMed Web of Science ®Google Scholar
• Arya V, Kiser JJ. 2016. Role of transporters in drug development. J Clin Pharmacol. 56(7):S7–S10.
   PubMedGoogle Scholar
• Balimane PV, Marino A, Chong S. 2008. P-gp inhibition potential in cell-based models: which “calculation” method is the most accurate? AAPS J. 10(4):577–586.
   PubMed Web of Science ®Google Scholar
• Balimane PV, Patel K, Marino A, Chong S. 2004. Utility of 96 well Caco-2 cell system for increased throughput of P-gp screening in drug discovery. Eur J Pharm Biopharm. 58(1):99–105.
   PubMed Web of Science ®Google Scholar
• Bentz J, O’Connor MP, Bednarczyk D, Coleman J, Lee C, Palm J, Pak YA, Perloff ES, Reyner E, Balimane P, et al. 2013. Variability in P-glycoprotein inhibitory potency (IC50) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria. Drug Metab Dispos. 41(7):1347–1366.
   PubMed Web of Science ®Google Scholar
• Bhoopathy S, Bode C, Naageshwaran V, Weiskircher-Hildebrandt EA, Hidalgo IJ. 2014. Principles and experimental considerations for in vitro transporter interaction assays. Methods Mol Biol. 1113:229–252.
   PubMedGoogle Scholar
• Brouwer KL, Keppler D, Hoffmaster KA, Bow DA, Cheng Y, Lai Y, Palm JE, Stieger B, Evers R. 2013. In vitro methods to support transporter evaluation in drug discovery and development. Clin Pharmacol Ther. 94(1):95–112.
   PubMed Web of Science ®Google Scholar
• Cheng Y, El-Kattan A, Zhang Y, Ray AS, Lai Y. 2016. Involvement of drug transporters in organ toxicity: the fundamental basis of drug discovery and development. Chem Res Toxicol. 29(4):545–563.
   PubMed Web of Science ®Google Scholar
• Cook JA, Feng B, Fenner KS, Kempshall S, Liu R, Rotter C, Smith DA, Troutman MD, Ullah M, Lee CA. 2010. Refining the in vitro and in vivo critical parameters for P-glycoprotein, [I]/IC50 and [I2]/IC50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies. Mol Pharmaceutics. 7(2):398–411.
   PubMed Web of Science ®Google Scholar
• Crowe A, Wong P. 2004. pH dependent uptake of loperamide across the gastrointestinal tract: an in vitro study. Drug Dev Ind Pharm. 30(5):449–459.
   PubMed Web of Science ®Google Scholar
• Crowe A, Wright C. 2012. The impact of P-glycoprotein mediated efflux on absorption of 11 sedating and less-sedating antihistamines using Caco-2 monolayers. Xenobiotica. 42(6):538–549.
   PubMed Web of Science ®Google Scholar
• Elsby R, Surry DD, Smith VN, Gray AJ. 2008. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions. Xenobiotica. 38(7–8):1140–1164.
   PubMed Web of Science ®Google Scholar
• Estudante M, Morais JG, Soveral G, Benet LZ. 2013. Intestinal drug transporters: an overview. Adv Drug Deliv Rev. 65(10):1340–1356.
   PubMed Web of Science ®Google Scholar
• European Medicinal Agency. 2012. Guideline on the investigation of drug interactions. Amstersam (The Netherlands): EMA; [accessed 2022 June 16]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf.
   Google Scholar
• Food and Drug Administration. 2020. Guidance for industry: in vitro drug interaction studies - cytochrome P450 enzyme- and transporter-mediated drug interactions. Silver Spring (MD): USFDA; [accessed 2022 June 16]. https://www.fda.gov/media/134582/download.
   Google Scholar
• Galetin A, Gertz M, Houston JB. 2008. Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions. Expert Opin Drug Metab Toxicol. 4(7):909–922.
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Huang S-M, Tweedie DJ, Benet LZ, Brouwer KLR, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, et al. 2010. Membrane transporters in drug development. Nat Rev Drug Discov. 9(3):215–236.
   PubMed Web of Science ®Google Scholar
• Hayeshi R, Hilgendorf C, Artursson P, Augustijns P, Brodin B, Dehertogh P, Fisher K, Fossati L, Hovenkamp E, Korjamo T, et al. 2008. Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. Eur J Pharm Sci. 35(5):383–396.
   PubMed Web of Science ®Google Scholar
• Hodin S, Basset T, Jacqueroux E, Delezay O, Clotagatide A, Perek N, Mismetti P, Delavenne X. 2018. In vitro comparison of the role of P-glycoprotein and breast cancer resistance protein on direct oral anticoagulants disposition. Eur J Drug Metab Pharmacokinet. 43(2):183–191.
   PubMed Web of Science ®Google Scholar
• ICH Harmonised Guideline. 2022. Drug interaction studies. Geneva (Switzerland): ICH; [accessed 2022 August 22]. https://database.ich.org/sites/default/files/M12_Step1_draft_Guideline_2022_0524.pdf.
   Google Scholar
• Kamiyama E, Sugiyama D, Nakai D, Miura S, Okazaki O. 2009. Culture period-dependent change of function and expression of ATP-binding cassette transporters in Caco-2 cells. Drug Metab Dispos. 37(9):1956–1962.
   PubMed Web of Science ®Google Scholar
• Keogh JP, Kunta JR. 2006. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. Eur J Pharm Sci. 27(5):543–554.
   PubMed Web of Science ®Google Scholar
• Kishimoto W, Ishiguro N, Ludwig-Schwellinger E, Ebner T, Schaefer O. 2014. In vitro predictability of drug-drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I]2/IC50 threshold. Drug Metab Dispos. 42(2):257–263.
   PubMed Web of Science ®Google Scholar
• Köck K, Brouwer KLR. 2012. A perspective on efflux transport proteins in the liver. Clin Pharmacol Ther. 92(5):599–612.
   PubMed Web of Science ®Google Scholar
• Korjamo T, Honkakoski P, Toppinen MR, Niva S, Reinisalo M, Palmgrén JJ, Mönkkönen J. 2005. Absorption properties and P-glycoprotein activity of modified Caco-2 cell lines. Eur J Pharm Sci. 26(3–4):266–279.
   PubMed Web of Science ®Google Scholar
• Lee CA, Kalvass JC, Galetin A, Zamek-Gliszczynski MJ. 2014. ITC commentary on the prediction of digoxin clinical drug-drug interactions from in vitro transporter assays. Clin Pharmacol Ther. 96(3):298–301.
   PubMed Web of Science ®Google Scholar
• Lee SC, Arya V, Yang X, Volpe DA, Zhang L. 2017. Evaluation of transporters in drug development: current status and contemporary issues. Adv Drug Deliv Rev. 116:100–118.
   PubMed Web of Science ®Google Scholar
• Ma JD, Tsunoda SM, Bertino JS, Trivedi M, Beale KK, Nafziger AN. 2010. Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation. Clin Pharmacokinet. 49(4):223–237.
   PubMed Web of Science ®Google Scholar
• Mahringer A, Fricker G. 2016. ABC transporters at the blood-brain barrier. Expert Opin Drug Metab Toxicol. 12(5):499–508.
   PubMed Web of Science ®Google Scholar
• Miliotis T, Ali L, Palm JE, Lundqvist AJ, Ahnoff M, Andersson TB, Hilgendorf C. 2011. Development of a highly sensitive method using liquid chromatography-multiple reaction monitoring to quantify membrane P-glycoprotein in biological matrices and relationship to transport function. Drug Metab Dispos. 39(12):2440–2449.
   PubMed Web of Science ®Google Scholar
• Morrissey KM, Stocker SL, Wittwer MB, Xu L, Giacomini KM. 2013. Renal transporters in drug development. Annu Rev Pharmacol Toxicol. 53:503–529.
   PubMed Web of Science ®Google Scholar
• Nader AM, Foster DR. 2014. Suitability of digoxin as a P-glycoprotein probe: implications of other transporters on sensitivity and specificity. J Clin Pharmacol. 54(1):3–13.
   PubMed Web of Science ®Google Scholar
• Neuhoff S, Ungell AL, Zamora I, Artursson P. 2003. pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm Res. 20(8):1141–1148.
   PubMed Web of Science ®Google Scholar
• Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. 2006. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther. 316(1):336–348.
   PubMed Web of Science ®Google Scholar
• Patil AG, D’Souza R, Dixit N, Damre A. 2011. Validation of quinidine as a probe substrate for the in vitro P-gp inhibition assay in Caco-2 cell monolayer. Eur J Drug Metab Pharmacokinet. 36(3):115–119.
   PubMed Web of Science ®Google Scholar
• Perloff ES, Mason AK, Kapadnis S, Khum W, Fox LG, Stresser DM. 2011. Comparison of digoxin efflux inhibition in Caco-2 and MDR1-LLC-PK1 cell monolayers. Drug Metab Rev. 43(S2):193.
   Google Scholar
• Pharmaceuticals and Medical Devices Agency. 2018. Drug interaction guideline for drug development and labelling recommendations. Tokyo (Japan): PhMDA; [accessed 2022 June 16]. https://www.pmda.go.jp/files/000228122.pdf.
   Google Scholar
• Poirier A, Cascais AC, Bader U, Portmann R, Brun ME, Walter I, Hillebrecht A, Ullah M, Funk C. 2014. Calibration of in vitro multidrug resistance protein 1 substrate and inhibition assays as a basis to support the prediction of clinically relevant interactions in vivo. Drug Metab Dispos. 42(9):1411–1422.
   PubMed Web of Science ®Google Scholar
• Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, Serabjit-Singh CJ, Polli JW. 2006. In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos. 34(5):786–792.
   PubMed Web of Science ®Google Scholar
• Senarathna SM, Crowe A. 2015. The influence of passage number for Caco2 cell models when evaluating P-gp mediated drug transport. Pharmazie. 70(12):798–803.
   PubMed Web of Science ®Google Scholar
• Shirasaka Y, Sakane T, Yamashita S. 2008. Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane. J Pharm Sci. 97(1):553–565.
   PubMed Web of Science ®Google Scholar
• Siissalo S, Laitinen L, Koljonen M, Vellonen KS, Kortejärvi H, Urtti A, Hirvonen J, Kaukonen AM. 2007. Effect of cell differentiation and passage number on the expression of efflux proteins in wild type and vinblastine-induced Caco-2 cell lines. Eur J Pharm Biopharm. 67(2):548–554.
   PubMed Web of Science ®Google Scholar
• Sugimoto H, Matsumoto SI, Tachibana M, Niwa S, Hirabayashi H, Amano N, Moriwaki T. 2011. Establishment of in vitro P-glycoprotein inhibition assay and its exclusion criteria to assess the risk of drug-drug interaction at the drug discovery stage. J Pharm Sci. 100(9):4013–4023.
   PubMed Web of Science ®Google Scholar
• Tang F, Horie K, Borchardt RT. 2002. Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 19(6):765–772.
   PubMed Web of Science ®Google Scholar
• Taub ME, Podila L, Ely D, Almeida I. 2005. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity. Drug Metab Dispos. 33(11):1679–1687.
   PubMed Web of Science ®Google Scholar
• Trevethan R. 2017. Sensitivity, specificity, and predictive values: foundations, liabilities, and pitfalls in research and practice. Front Public Health. 5:307.
   PubMed Web of Science ®Google Scholar
• Volpe DA. 2011. Drug permeability and transporter assays in Caco-2 and MDCK cell lines. Future Med Chem. 3(16):2063–2077.
   PubMed Web of Science ®Google Scholar
• Volpe DA. 2016. Transporter assays as useful in vitro tools in drug discovery and development. Expert Opin Drug Discov. 11(1):91–103.
   PubMed Web of Science ®Google Scholar
• Volpe DA, Hamed SS, Zhang LK. 2014. Use of different parameters and equations for calculation of IC50 values in efflux assays: potential sources of variability in IC50 determination. AAPS J. 16(1):172–180.
   PubMed Web of Science ®Google Scholar
• Zhou T, Arya V, Zhang L. 2019. Comparing various in vitro prediction methods to assess the potential of a drug to inhibit P-glycoprotein (P-gp) transporter in vivo. J Clin Pharmacol. 59(8):1049–1060.
   PubMed Web of Science ®Google Scholar